"Before I explain, I want to clarify that I firmly believe in body autonomy. If someone chooses to take a weight loss medication, they should be able to do so without judgment. I hope all potential users are fully informed about the risks and benefits of these medications and are followed responsibly by medical providers. Ideally, they would also be screened for a current or past eating disorder or any other condition that might contraindicate the use of GLP-1s and GIPs."
"But how effective are these medications at enabling sustainable weight loss? And do they improve body image? These are questions for which we don't yet have concrete answers. In my view, "sustainable" should mean lasting for many years-ideally, a lifetime. Yet the longest longitudinal study on these drugs followed participants for just four years, and most existing research spans only one or two years. These studies suggest a 10-15% reduction in body weight over that ti"
Semaglutide and tirzepatide (Wegovy, Ozempic, Zepbound, Mounjaro) have generated widespread attention as GLP-1 and GIP receptor agonists. Strong evidence supports their use for health conditions like diabetes. Longitudinal research on weight loss from these drugs is limited, with most studies lasting one to two years and the longest following participants for four years. Short-term trials show approximately 10–15% body weight reduction over those study periods. Interest in GLP-1s is higher among people who engage in maladaptive eating behaviors. Higher body appreciation appears to decrease the likelihood of pursuing weight-loss medications. Screening for eating disorders is advisable before prescribing.
Read at Psychology Today
Unable to calculate read time
Collection
[
|
...
]